Virtual Library
Start Your Search
Yueping Liu
Author of
-
+
P2.01 - Advanced NSCLC (Not CME Accredited Session) (ID 950)
- Event: WCLC 2018
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall
-
+
P2.01-114 - The Correlation Among PD-L1 Expression, TMB and Lung Immune Prognostic Index in Chinese Patients with Advanced Lung Adenocarcinoma (ID 13896)
16:45 - 18:00 | Author(s): Yueping Liu
- Abstract
Background
Anti-PD-1/PD-L1 immunotherapy was approved as first-line treatment on the part of NSCLC patients, but not all can benefit, some studies have shown that PD-L1 expression, Tumor Mutation Burden (TMB) and Lung Immune Prognostic Index (LIPI) can be respectively used as an effect predictor of NSCLC immunotherapy. We aim to explore the correlation of the three predictors in Chinese patients with advanced lung adenocarcinoma.
a9ded1e5ce5d75814730bb4caaf49419 Method
We enrolled 53 biopsy specimens of the advanced lung adenocarcinoma patients from four China centers, measured complete blood cell counts and lactate dehydrogenase (LDH) before biopsy, detected PD-L1 level by three IHC assays (22C3, 28-8, SP263) ,driver genes and TMB by NGS. LIPI was divided into three groups.
4c3880bb027f159e801041b1021e88e8 Result
In the cohort, 28 (52.8%) were male; median age was 59 (range, 34-81) years. There were 7 (13.2%, 7/53) with positive PD-L1(≥50%) based on 22C3. Three assays were highly concordant for tumor cells (ρ=0.740-0.826), lower for immune cells (ρ=0.462-0.543). Six (of 34,17.6%) were high TMB (at least 10/Mb). All were male (p=0.031), in which 5 were associated with TP53 mutation, 3 had DNA replication or damage repair–related gene mutations and 4 showed high PD-L1 on immune cells (p=0.031). LIPI didn't show significant correlation with PD-L1 or TMB (p＞0.05). 3 of 20 with targetable driver gene alterations (ALK/EGFR/ROS1) were high PD-L1 or TMB. In the targetable driver gene wild cases, there were 8 (of 14) high PD-L1 or TMB.
8eea62084ca7e541d918e823422bd82e Conclusion
28-8, 22C3 and SP263 assays were aligned on tumor cell staining.There was no significant correlation among PD-L1, TMB and LIPI, which may be independent and complemented. High TMB might occur in male, show high PD-L1 on immune cells and accompanied with TP53 mutations. High PD-L1 or TMB was frequently found in the targetable driver gene wild cases.The prognostic value of PD-L1 and TMB on advanced NSCLC will be further followed.
6f8b794f3246b0c1e1780bb4d4d5dc53
-
+
P2.03 - Biology (Not CME Accredited Session) (ID 952)
- Event: WCLC 2018
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall
-
+
P2.03-09 - The Real World of NTRK Fusion Data in the Chinese Lung Cancer Populations: A Multicenter Study (ID 11307)
16:45 - 18:00 | Author(s): Yueping Liu
- Abstract
Background
NTRK fusions have been recently identified as a therapeutic target in a rare fraction of Caucasian patients with lung cancer (3.3%). The aim of this study was to evaluate the prevalence of NTRK fusions in Chinese lung cancer populations, which had not been reported earlier, and to describe targeting potential in Chinese lung cancer populations.
a9ded1e5ce5d75814730bb4caaf49419 Method
A multicenter study in China was initiated from February 2014, and lung cancer patients have been enrolled as of December 2017. Capture-based comprehensive genomic profiling was performed on 2719 lung cancer FFPE samples (non-squamous/squamous/small=2061/349/309) sequenced to a mean coverage depth of > 650X for up to 381 cancer-related genes. Genomic alterations (GA) included short variant (SV) base subs and insertions/deletions, copy number alterations, and rearrangements/fusions. Tumor mutational burden (TMB; mut/Mb) was calculated on up to 1.2 Mb of sequenced DNA.
4c3880bb027f159e801041b1021e88e8 Result
Of this entire cohort, just one (0.04%) patient was identified with a TPM3-NTRK1 fusion. The patient was diagnosed with SCLC. TPM3-NTRK1 fusion was found by biopsy using NGS, the genes co-altered with NTRK fusion was no concurrent with KRAS, EGFR, ALK, ROS1, or other known drivers were identified in the study cohort cases.
8eea62084ca7e541d918e823422bd82e Conclusion
NTRK fusions are a rare molecular subtype in Chinese lung cancer populations. Given clinical evidence for the activity of targeted therapy approaches, molecular eligibility for clinical trials of larotrectinib or entrectinib should include these fusion subtypes. The clinical evidence for responsiveness of NTRK fusions driven lung cancer provides an opportunity to personalize treatments and improve clinical outcomes for patients.
6f8b794f3246b0c1e1780bb4d4d5dc53
